ProCeTH: Pharmacological Study of Cefazolin Antibioprophylaxis in Liver Transplantation

Sponsor
University Hospital, Tours (Other)
Overall Status
Withdrawn
CT.gov ID
NCT04280237
Collaborator
(none)
0
1
17
0

Study Details

Study Description

Brief Summary

This study describes Cefazolin pharmacokinetics variation to target levels during liver transplantation.

Condition or Disease Intervention/Treatment Phase
  • Other: Blood samples

Detailed Description

Cefazolin is one of the many drugs used in antibiotic prophylaxis during liver transplantation. However there are no study describing its pharmacokinetics during liver transplantation.

Due to the severe pharmacokinetics interactions caused by both prior hepatopathy and surgical techniques we suppose that Cefazolin blood levels are very different from those targeted for antibiotic prophylaxis.

This study aim to describe pharmacokinetics of Cefazolin during liver transplantation in order to adapt antibiotic prophylaxis strategy in case of unadapted measured levels.

Study Design

Study Type:
Observational
Actual Enrollment :
0 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Pharmacological Study of Cefazolin Antibioprophylaxis in Liver Transplantation
Anticipated Study Start Date :
Mar 1, 2020
Actual Primary Completion Date :
Mar 18, 2020
Actual Study Completion Date :
Mar 18, 2020

Arms and Interventions

Arm Intervention/Treatment
Cefazolin in liver transplantation

Patient undergoing liver transplant surgery and receiving antibiotic prophylaxis with Cefazolin

Other: Blood samples
Blood samples

Outcome Measures

Primary Outcome Measures

  1. Cefazolin blood concentration [Baseline up to 10 hours]

    Cefazolin blood concentration will be measured at the moment of surgical incision and every hour until end of surgery

Secondary Outcome Measures

  1. Assess correlations between Cefazolin blood concentration and CHILD-PUGH score [baseline]

    Patient's CHILD-PUGH score before transplantation

  2. Assess correlations between Cefazolin blood concentration and MELD score [baseline]

    Patient's MELD score before transplantation

  3. Assess correlations between Cefazolin blood concentration and Cirrhosis etiology [baseline]

    Cause of cirrhosis

  4. Assess correlations between Cefazolin blood concentration and Transplantation indication [baseline]

    Cause leading to transplantation

  5. Assess correlations between Cefazolin blood concentration and Transjugular intrahepatic portosystemic shunt (TIPS) [baseline]

    Medical history of TIPS

  6. Assess correlations between Cefazolin blood concentration and Creatinine [baseline]

    Creatinine levels will be measured before transplantation

  7. Assess correlations between Cefazolin blood concentration and Hemodialysis [baseline]

    Patient needing hemodialysis before liver transplantation

  8. Assess correlations between Cefazolin blood concentration and Albumin [baseline]

    Albumin levels will be measured before transplantation

  9. Assess correlations between Cefazolin blood concentration and Surgery duration [End of surgery]

    Time of surgical incision and end of the surgery will be noted

  10. Assess correlations between Cefazolin blood concentration and Portal vein clamping time [End of surgery]

    Time of portal vein clamping and declamping during realization of vascular anastomosis will be noted

  11. Assess correlations between Cefazolin blood concentration and Ascitis [Baseline]

    Volume of ascitis drained at the beginning of surgery

  12. Assess correlations between Cefazolin blood concentration and Urine output [End of surgery]

    Volume of urine output during surgery

  13. Assess correlations between Cefazolin blood concentration and Blood loss [End of surgery]

    Blood loss quantification will be done throughout surgery

  14. Assess correlations between Cefazolin blood concentration and Red cell transfusion unit [End of surgery]

    The number of red cell units transfused during transplantation will be counted at the end of surgery

  15. Assess correlations between Cefazolin blood concentration and Platelet transfusion unit [End of surgery]

    The number of platelet units transfused during transplantation will be counted at the end of surgery

  16. Assess correlations between Cefazolin blood concentration and Plasma transfusion unit [End of surgery]

    The number of plasma units transfused during transplantation will be counted at the end of surgery

  17. Assess correlations between Cefazolin blood concentration and Intraoperative blood salvage [End of surgery]

    Intraoperative blood salvage transfusion volume during surgery

  18. Assess correlations between Cefazolin blood concentration and Crystalloid infusion [End of surgery]

    Assess correlations between Cefazolin blood concentration and Volume of crystalloid infusion during surgery

  19. Assess correlations between Cefazolin blood concentration and Colloid infusion [End of surgery]

    Volume of colloid infusion during surgery

  20. Assess correlations between Cefazolin blood concentration and Basal cardiac index [Baseline]

    Cardiac index value at the beginning of surgery

  21. Assess correlations between Cefazolin blood concentration and Minimal cardiac index [End of surgery]

    Minimal index value during surgery

  22. Assess correlations between Cefazolin blood concentration and Surgical site infection [Day 28]

    Number of patient with surgical site infection in the 28 days post-surgery

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age over 18

  • patient undergoing liver transplantation

  • receiving Cefazolin as perioperative antibiotic prophylaxis to prevent surgical site infections

Exclusion Criteria:
  • pregnant women

  • legal protection or protected adults

  • ongoing antibiotic treatment before liver transplantation

  • patient inability to receive information or express opposition to the study.

  • patient refusing participation

Contacts and Locations

Locations

Site City State Country Postal Code
1 Surgical intensive care unit, University Hospital, Tours Tours France 37044

Sponsors and Collaborators

  • University Hospital, Tours

Investigators

  • Principal Investigator: Anne-Charlotte TELLIER, MD, University Hospital, Tours

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Tours
ClinicalTrials.gov Identifier:
NCT04280237
Other Study ID Numbers:
  • RIPH3-RNI20/ProCeTH
  • 2020-A00405-34
First Posted:
Feb 21, 2020
Last Update Posted:
Apr 29, 2021
Last Verified:
Apr 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Tours
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 29, 2021